
## Ursula Theuretzbacher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8194353/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 934-943.	1.3	5
2	Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe, The, 2022, 3, e795-e802.	3.4	17
3	Investigator-initiated Randomized Controlled Trials in Infectious Diseases: Better Value for Money for Registration Trials of New Antimicrobials. Clinical Infectious Diseases, 2021, 72, 1259-1264.	2.9	4
4	Role of new antibiotics for KPC-producing <i>Klebsiella pneumoniae</i> . Journal of Antimicrobial Chemotherapy, 2021, 76, i47-i54.	1.3	17
5	The global preclinical antibacterial pipeline. Nature Reviews Microbiology, 2020, 18, 275-285.	13.6	442
6	Dual-mechanism antibiotics. Nature Microbiology, 2020, 5, 984-985.	5.9	10
7	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities. Clinical Microbiology and Infection, 2020, 26, 1630-1635.	2.8	16
8	Critical analysis of antibacterial agents in clinical development. Nature Reviews Microbiology, 2020, 18, 286-298.	13.6	204
9	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: inÂvitro synergism is not associated with better clinical outcomes. Clinical Microbiology and Infection, 2020, 26, 1185-1191.	2.8	46
10	Non-traditional Antibacterial Therapeutic Options and Challenges. Cell Host and Microbe, 2019, 26, 61-72.	5.1	134
11	Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infectious Diseases, The, 2019, 19, e40-e50.	4.6	161
12	The small-molecule antibiotics pipeline: 2014–2018. Nature Reviews Drug Discovery, 2019, 18, 739-739.	21.5	47
13	Unavailability of old antibiotics threatens effective treatment for common bacterial infections. Lancet Infectious Diseases, The, 2018, 18, 242-244.	4.6	13
14	Colistin versus colistin plus meropenem for severe infections Authors' reply. Lancet Infectious Diseases, The, 2018, 18, 495-496.	4.6	1
15	Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women. JAMA - Journal of the American Medical Association, 2018, 319, 1781.	3.8	147
16	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 391-400.	4.6	400
17	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 318-327.	4.6	3,672
18	Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin. Clinical Microbiology and Infection, 2018, 24, 1231-1233.	2.8	22

URSULA THEURETZBACHER

#	Article	IF	CITATIONS
19	Concentration-dependent plasma protein binding: Expect the unexpected. European Journal of Pharmaceutical Sciences, 2018, 122, 341-346.	1.9	23
20	New drugs – will they solve the problem of resistance to antibiotics?. Clinical Microbiology and Infection, 2017, 23, 695-696.	2.8	5
21	Global antimicrobial resistance in Gram-negative pathogens and clinical need. Current Opinion in Microbiology, 2017, 39, 106-112.	2.3	120
22	Antibiotic innovation for future public health needs. Clinical Microbiology and Infection, 2017, 23, 713-717.	2.8	29
23	Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. International Journal of Antimicrobial Agents, 2017, 49, 98-101.	1.1	31
24	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 2016, 6, e009956.	0.8	41
25	Antibacterial innovation in European SMEs. Nature Reviews Drug Discovery, 2016, 15, 812-813.	21.5	8
26	Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. Journal of Antimicrobial Chemotherapy, 2015, 70, 2456-2464.	1.3	189
27	Reviving old antibiotics. Journal of Antimicrobial Chemotherapy, 2015, 70, 2177-2181.	1.3	79
28	Revival of old antibiotics: structuring the re-development process to optimize usage. Clinical Microbiology and Infection, 2015, 21, 878-880.	2.8	11
29	PK/PD of Oxazolidinones. , 2014, , 401-443.		0
30	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	4.6	745
31	Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. Clinical Infectious Diseases, 2014, 58, 139-141.	2.9	60
32	Impact of availability of guidelines and active surveillance in reducing the incidence of ventilator-associated pneumonia in Europe and worldwide. BMC Infectious Diseases, 2014, 14, 199.	1.3	4
33	Product information for parenteral colistin varies substantially across Europe. Journal of Antimicrobial Chemotherapy, 2014, 69, 1987-1992.	1.3	20
34	Combination therapy for carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2014, 69, 2305-2309.	1.3	179
35	Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. Journal of Global Antimicrobial Resistance, 2013, 1, 117-122.	0.9	5
36	Global antibacterial resistance: The never-ending story. Journal of Global Antimicrobial Resistance, 2013, 1, 63-69.	0.9	116

#	Article	IF	CITATIONS
37	Pharmacokinetic and Pharmacodynamic Issues for Antimicrobial Therapy in Patients With Cancer. Clinical Infectious Diseases, 2012, 54, 1785-1792.	2.9	57
38	Accelerating resistance, inadequate antibacterial drug pipelines and international responses. International Journal of Antimicrobial Agents, 2012, 39, 295-299.	1.1	128
39	Protein Binding: Do We Ever Learn?. Antimicrobial Agents and Chemotherapy, 2011, 55, 3067-3074.	1.4	212
40	Resistance drives antibacterial drug development. Current Opinion in Pharmacology, 2011, 11, 433-438.	1.7	73
41	Update on antibacterial and antifungal drugs – can we master the resistance crisis?. Current Opinion in Pharmacology, 2011, 11, 429-432.	1.7	16
42	Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resistance Updates, 2011, 14, 107-117.	6.5	175
43	The Effect of Critical Illness on Drug Distribution. Current Pharmaceutical Biotechnology, 2011, 12, 2030-2036.	0.9	31
44	Antibacterial Distribution and Drug–Drug Interactions in Cancer Patients. , 2011, , 443-454.		1
45	Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clinical Pharmacokinetics, 2010, 49, 379-396.	1.6	210
46	Future antibiotics scenarios: is the tide starting to turn?. International Journal of Antimicrobial Agents, 2009, 34, 15-20.	1.1	117
47	Tissue concentrations: do we ever learn?. Journal of Antimicrobial Chemotherapy, 2007, 61, 235-237.	1.3	333
48	Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?. Current Opinion in Pharmacology, 2007, 7, 498-504.	1.7	56
49	Pharmacokinetic/Pharmacodynamic Profile of Voriconazole. Clinical Pharmacokinetics, 2006, 45, 649-663.	1.6	386
50	Nature's clarion call of antibacterial resistance: are we listening?. Current Opinion in Investigational Drugs, 2006, 7, 158-66.	2.3	15
51	Urinary Excretion and Bactericidal Activities of a Single Oral Dose of 400 Milligrams of Fleroxacin versus a Single Oral Dose of 800 Milligrams of Pefloxacin in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 1998, 42, 1659-1665.	1.4	22